Moderna reported 29% revenue growth in the third quarter and GAAP net income of $162 million. Management raised full-year guidance to 15%-25% revenue growth, up from prior guidance of up to 10% growth. Shares fluctuated but were up 6% intraday on Nov. 6.
The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology.
Moderna's Alexion partnership was terminated in 2017 after failure to find a safe but effective dose for the lead program, which could foreshadow difficulty finding a therapeutic window beyond low-dose vaccine programs.
Metric | MRNA | BNTX | PFE |
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 13.45 |
Price/Book Value | 15.90 | 1.08 | 1.87 |
Price/Sales | 42.32 | 7.79 | 2.63 |
Price/Cash Flow | — | — | 11.33 |
Metric | MRNA | BNTX | PFE |
|---|---|---|---|
Quick Ratio | 3.34 | 8.43 | 1.00 |
Current Ratio | 3.62 | 8.55 | 1.42 |
Interest Coverage | −49.00 | — | 2.39 |
Metric | MRNA | BNTX | PFE |
|---|---|---|---|
Return on Assets (Normalized) | −20.21% | −3.31% | 8.49% |
Return on Equity (Normalized) | −31.30% | −3.78% | 19.73% |
Return on Invested Capital (Normalized) | −27.15% | −4.37% | 12.71% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$TWcFC | LOCK|$@?F! | $140B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|N%@bJt@ | LOCK|dqtpt | $95B | |||
| argenx SE ADR ARGX | LOCK|@X>$!> | LOCK|@& | $60B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|mnNFl<@ | LOCK|V@C | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|h?#Rm^& | LOCK|R^>w | $31B | |||
| Incyte Corp INCY | LOCK|<<GzNcR | LOCK|@! | $25B | |||
| BioNTech SE ADR BNTX | LOCK|^ZhN^<^ | LOCK|KLJ | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%Z>%?F | LOCK|qq%& | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|jR%TW#y | LOCK|B# | $16B |
United States